

**Improving Basic Research, Clinical Trial Infrastructure, and Community
Engagement to Support Drug Development for ALS**

January 27 & 28, 2021

Participant List

Eleni Anagnostiadis

Director, Patient Affairs and Stakeholder
Engagement, U.S. Food and Drug
Administration

Jinsy Andrews

Associate Professor of Neurology, Director of
Neuromuscular Clinical Trials, Columbia
University

Nazneen Barwick

Director, Clinical Development, GlaxoSmithKline

Eric Bastings

Deputy Director, Office of Neuroscience; Acting
Director, Division of Neurology 1, Office of
Neuroscience, U.S. Food and Drug
Administration

Emily Baxi

Executive Director, The Robert Packard Center
for ALS Research at Johns Hopkins

Richard Bedlack

Director, Duke ALS Clinic, Professor of
Neurology, Duke University

Michael Benatar

Professor of Neurology, Walter Bradley Chair in
ALS Research, University of Miami

Visar Berisha

Chief Analytics Officer, Co-Founder, Aural
Analytics

Kristina Bowyer

Vice President, Patient Centric Drug
Development, Ionis Pharmaceuticals

Beth Boyer

Research Associate, Duke-Margolis Center for
Health Policy

Shawn Brooks

Health Communications Specialist, Patient
Affairs and Stakeholder Engagement, U.S. Food
and Drug Administration

Wilson Bryan

Director, Office of Cellular, Tissue, and Gene
Therapies, U.S. Food and Drug Administration

Matthew Buck

Vice President, Regulatory Affairs, Ionis
Pharmaceuticals

Teresa Buracchio

Deputy Director, Division of Neurology 1, U.S.
Food and Drug Administration

Michelle Campbell

Senior Clinical Analyst for Stakeholder
Engagement and Clinical Outcomes, Office of
Neuroscience, U.S. Food and Drug
Administration

Danielle Carnival

Chief Executive Officer, I AM ALS

Patrizia Cavazzoni

Acting Director, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration

Lakeecha Chenjo

Program Analyst, Stakeholder Engagement,
Office of External Affairs, U.S. Food and Drug
Administration

Susan Chittooran

Patient Engagement Project Manager, Office of Patient Affairs, U.S. Food and Drug Administration

Alecia Clary

Associate Director for Research, Reagan-Udall Foundation for the FDA

Joshua Cohen

Chief Executive Officer, Co-Founder, Amylyx

Mildred Cooper

U.S. Food and Drug Administration

Rebecca Crean

Director, Clinical Development, Ionis Pharmaceuticals

Dayle Cristinzio

Director, Stakeholder Engagement, Office of External Affairs, U.S. Food and Drug Administration

Merit Cudkowicz

Chief of the Massachusetts General Hospital Neurology Service, Director, Sean M. Healey & AMG Center at MGH

Kuldip Dave

Vice President of Research, The ALS Association

Billy Dunn

Director, Office of Neuroscience, U.S. Food and Drug Administration

Clare Durrett

Strategic Advisor—Advocacy, Legislation, and Communications, Team Gleason

Noam Epstein

Neuroscience Discovery Medicine Physician, GlaxoSmithKline

Meredith Estess

President, Co-Founder, Project ALS

Valerie Estess

Director of Research, Co-Founder, Project ALS

Toby Ferguson

Head of the Neuromuscular Development Unit, Biogen

James Flahive

Senior Advisor, Office of the Commissioner, U.S. Food and Drug Administration

Erin Fleming

Director of Research Operations, Project ALS

Lois Freed

Division Director, Division of Pharmacology/Toxicology, Office of Neuroscience, U.S. Food and Drug Administration

Emily Freilich

Team Leader, Division of Neurology 1, U.S. Food and Drug Administration

Andrea Furia-Helms

Director, Patient Affairs, U.S. Food and Drug Administration

William Garofano

Clinical Trial Manager, AZTherapies

Robert L. Glanzman

Chief Medical Officer, Clene Nanomedicine, Inc.

John Goodrich

Health Program Coordinator, Stakeholder Engagement, Office of External Affairs, U.S. Food and Drug Administration

Philip Green

ALS Research Ambassador

Amelie Gubit

Program Director, Division of Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Ron Hoffman

Executive Director, Founder Compassionate Care ALS

Jonathan Hollander

Program Director, Genes, Environment and Health Branch, National Institute of Environmental Health Sciences, National Institutes of Health

Megan Howard

Congressional Affairs Specialist, Office of Legislation, U.S. Food and Drug Administration

Nicholas Hulbig

Manager, Clinical Trial, AZTherapies

Sophia Jeon

Health Science Policy Analyst, Office of Science and Policy Planning, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Andreas Kalmes

Director, Clinical Research, Revalesio

Sadhna Khatri

Associate Director of Operations, Professional Affairs and Stakeholder Engagement, U.S. Food and Drug Administration

Justin Klee

Chief Executive Officer, Co-Founder, Amylyx

Justin Kwan

Director, Neurodisorders Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Jane Larkindale

Executive Director, Duchenne Regulatory Sciences Consortium, Rare Disease Cures Accelerator-Data and Analytics Platform, Critical Path Institute

Diane Maloney

Associate Director for Policy, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Peter Marks

Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Mark McClellan

Director, Duke-Margolis Center for Health Policy

Paul Mehta

Principal Investigator, National ALS Registry, Centers for Disease Control and Prevention

Paul Melmeyer

Director, Regulatory Affairs, Muscular Dystrophy Association

Carolina Mendoza-Puccini

Program Officer, Division of Clinical Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Sandy Morris

ALS Patient Advocate, I AM ALS

Lindsey O’Keefe

Press Officer, Office of Media Affairs, U.S. Food and Drug Administration

Sabrina Paganoni

Co-Director, Massachusetts General Hospital Neurological Clinical Research Institute

Erin and Mick Palmesano

ALS Patient Advocates

Valerie J. Parker

Policy Analyst, Duke-Margolis Center for Health Policy

Melanie Quintana

Director, Senior Statistical Scientist, Berry Consultants

Irfan Qureshi

Vice President, Neurology, Biohaven
Pharmaceuticals

Manish Raisinghani

Chief Executive Officer, Target ALS

Morgan Romine

Chief of Staff, Duke-Margolis Center for Health
Policy

Anne Rowzee

Associate Director for Policy, Office of Tissues
and Advanced Therapies, U.S. Food and Drug
Administration

Sarah M. Sheehan

Managing Associate, Duke-Margolis Center for
Health Policy

Jeremy Shefner

Kemper and Ethel Marley Professor, Chair of
Neurology, Senior Vice President, Barrow
Neurological Institute

Alexander Sherman

Director, Center for Innovation and
Bioinformatics, Massachusetts General Hospital
Neurological Clinical Research Institute

Shannon K. Shryne

President and Co-Founder, Augie's Quest

Wendy Slavit

Health Program Coordinator, Patient Affairs,
U.S. Food and Drug Administration

LaShawn Sykes

Public Health Analyst, Center for Drug
Evaluation and Research, U.S. Food and Drug
Administration

Neil Thakur

Chief Mission Officer, The ALS Association

Julia (Julie) Tierney

Chief of Staff, Center for Biologics Evaluation
and Research, U.S. Food and Drug
Administration

Matt Toole

Patient Advocate

Bryan Traynor

Neurologist & Senior Investigator,
Neuromuscular Disease Research Section,
National Institute on Aging, National Institutes
of Health

Julienne Vaillancourt

Rare Disease Liason, Center for Biologics
Evaluation and Research, U.S. Food and Drug
Administration

Fernando Vieira

Chief Scientific Officer, ALS Therapy
Development Institute

Richard White

Policy Analyst, National Organization for Rare
Diseases

Lori Wiggins

Deputy Director, Division of Orthopedic
Devices, U.S. Food and Drug Administration

Lei Xu

Chief of General Medicine Branch 2, Division of
Clinical Evaluation and
Pharmacology/Toxicology, U.S. Food and Drug
Administration

Jill Yersak

Senior Director, Mission and Strategy, The ALS
Association